Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Cimetidine at the BBB–Cancer Translation Interface
2026-10-06
Cimetidine offers a useful case study in how H2 receptor pharmacology, gastrointestinal cancer hypotheses, and blood-brain barrier modeling can be connected without overstating the evidence. This article interprets the 2025 LLC-PK1-MDR1 surrogate barrier study, clarifies what it does and does not establish for cimetidine, and outlines a translational framework for positioning the compound as a research tool.
-
ICAA, HO-1, and HBV Replication
2026-10-06
A 2026 Antiviral Research study shows that isochlorogenic acid A (ICAA) suppresses HBV through multiple points in the viral life cycle, including transcription, cccDNA-associated output, capsid formation, and envelopment. Its central contribution is a mechanistic model linking HO-1 upregulation and intracellular ROS modulation with altered viral structural-protein chemistry, while leaving important questions about causality and in vivo relevance for future research.
-
Oligo (dT) 25 Beads for Mechanism-First RNA Analysis
2026-10-05
Oligo (dT) 25 Beads can be viewed not only as a capture reagent but as an analytical boundary between RNA enrichment and mechanistic inference. This article connects polyA tail mRNA capture to the PLPP1–phospholipid–AKT findings in a non-peer-reviewed lung-cancer preprint while defining evidence limits and study-design questions.
-
c-Myc Tag Peptide: Evidence and Limits
2026-10-05
The c-Myc tag peptide is a synthetic C-terminal epitope reagent intended for antibody-competition studies involving c-Myc-tagged fusion proteins. Product documentation supports its identity and reported physical specifications, while the cited IRF3 study provides biological context about transcription-factor stability rather than direct validation of this peptide.
-
TMRE and Sodium-Driven Mitochondrial Dysfunction
2026-10-04
A source-grounded overview of how TMRE-based mitochondrial membrane potential measurements can contextualize sodium-induced necrosis, with emphasis on the reported NECSO mechanism, conceptual applications, evidence strength, and interpretive limitations.
-
Salidroside, Mitophagy, and α-Amanitin Toxicity
2026-10-03
A 2024 study in Chemical Research in Toxicology examines how salidroside affects α-amanitin-induced injury in AML-12 mouse liver cells. Its central contribution is linking toxin-associated oxidative stress and apoptosis with PINK1/Parkin-mediated mitophagy and mitochondrial dysfunction, while also showing why the findings remain preliminary rather than evidence of a clinical antidote.
-
Bardoxolone Methyl Redox Research Workflows
2026-10-01
Bardoxolone methyl, also called CDDO methyl ester, gives researchers a practical way to connect Nrf2 activation, NF-kB suppression, oxidative stress, and disease-model phenotypes. This workflow-focused guide shows how to build reproducible assays and cautiously test whether redox control influences replication-stress responses.
-
HNF4A-AS1, Lipid Reprogramming, and Sorafenib Resistance
2026-10-01
A 2024 Theranostics study identifies the liver-enriched lncRNA HNF4A-AS1 as a regulator of sorafenib sensitivity in hepatocellular carcinoma. Its mechanistic model connects HNF4A-AS1 with METTL3-dependent m6A modification of DECR1 mRNA, PUFA abundance, and ferroptosis, providing a framework for studying metabolic resistance in HCC.
-
Actinomycin D for mRNA Stability Assays
2026-09-30
Actinomycin D converts transcriptional inhibition into a practical way to measure RNA decay, test pathway dependence, and model apoptosis in cancer cells. This workflow shows how ActD can extend TNBC studies such as YTHDF3–CENPI research while highlighting controls that prevent cytotoxicity and solubility artifacts from distorting interpretation.
-
ECL Western Blotting Substrate: Practical Guide
2026-09-30
ECL Western Blotting Substrate (SKU K2187) is a luminol-based, nonradioactive horseradish peroxidase detection reagent for chemiluminescent Western blot assays. It is intended for HRP-based immunoblot imaging with X-ray film or CCD cameras, not for fluorescent or radioisotopic detection workflows.
-
Biotin-tyramide for TSA and Proximity Mapping
2026-09-29
Biotin-tyramide converts HRP activity into localized, streptavidin-detectable signal for sensitive IHC, ISH, and spatial labeling workflows. This guide connects reproducible TSA setup with the live-cell proximity-labeling logic used to map transient glycan–protein interactions.
-
Ro 3306: CDK1 Inhibitor Workflow for Cell-Cycle Studies
2026-09-29
Ro 3306 provides a practical way to hold proliferating cells before mitotic entry, enabling cleaner analysis of mTORC1 oscillation, DNA repair, and checkpoint control. This guide combines cell cycle G2/M phase arrest, cancer cell synchronization, assay design, and troubleshooting for reproducible mechanistic studies.
-
Palonosetron for Preventing CINV: Evidence and Limits
2026-09-28
Ruhlmann and Herrstedt present a translational review of palonosetron hydrochloride, emphasizing how its long half-life, high 5-HT3-receptor affinity, and distinctive receptor interactions may improve protection against chemotherapy-induced nausea and vomiting. The review also shows why pharmacologic advantages must be interpreted alongside clinical endpoints, combination antiemetic therapy, treatment phase, and tolerability.
-
Live-Dead Cell Staining Kit I Guide
2026-09-28
A practical guide to applying Calcein AM/PI fluorescence live/dead detection in mammalian cell and biomaterial studies. Learn what SKU K2247 can show, how to plan controls and interpret the readout, and where the assay’s limits matter.
-
HyperScribe All in One mRNA Synthesis Kit Plus 1
2026-09-27
Build capped, nucleotide-modified, polyadenylated mRNA in a defined in vitro transcription workflow, then carry it forward to translation or delivery studies. A cryptococcal vaccine study illustrates why RNA synthesis is only one part of the design: sequence elements and LNP performance also shaped experimental outcomes.